Monday, July 12, 2010
Because current tests for prostate cancer recurrence are not
sensitive enough to parse out high- and low-risk patients, all patients are
subject to annual and sometimes semiannual office visits. Quanterix
Corp. is developing a single-molecule detection technology that could
identify those patients who do not require long-term follow-up and allow
physicians to better direct treatment to the higher-risk group.
Each year in the U.S., 100,000
men with biopsy-confirmed prostate cancer undergo a prostatectomy. Following
surgery, patients are monitored for disease recurrence for up to 15 years with
standard enzyme-linked immunosorbent assays (ELISAs) to detect prostate
specific antigen (KLK3, PSA).